Business Description
TuHURA Biosciences Inc. is a clinical-stage company based in Tampa, Florida, focused on developing new treatments that help the immune system fight cancer. Its lead treatment, IFx-2.0, is designed to improve the effectiveness of existing cancer drugs like Keytruda, with a Phase 3 trial currently being prepared. The company is also working on additional therapies, including antibody-based drugs that target cells known to suppress immune responses within tumors, as well as IFx-3.0, an mRNA-based treatment aimed at blood cancers. Founded in 1995 and formerly known as Morphogenesis Inc., TuHURA now operates as a subsidiary of CohBar Inc.
